Connect your AI

Precigen PGEN Long-term marketable securities

Long-term marketable securities at other companies

Bristol-Myers SquibbBMY

$366M+6.4%

Agios PharmaceuticalsAGIO

——

Ultragenyx PharmaceuticalRARE

——

Nektar TherapeuticsNKTR

——

Other financials

Income statement

Revenue$23.3M+1,634%

Operating income-$6.0M+73.5%

Net income-$7.9M+85.4%

EPS (diluted)-$0.02+88.9%

Balance sheet

Cash & equivalents$7.5M+23.5%

Total debt$98.3M+1,714%

Total equity$20.2M+244%

Total assets$138.6M+7.6%

Cash flow

Operating cash flow-$43.8M-168%

CapEx$258.0K-58.5%

Free cash flow-$44.1M-160%

Valuation

Market cap$1.93B+213%

Profitability

Gross margin83.6%—

Operating margin-2,890.9%—

Net margin-3,656%—

FCF margin-1,756.5%—

Returns & leverage

Return on equity-843.6%-1,103pp

Debt / equity4.9×—

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's long-term marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Precigen's long-term marketable securities?: Precigen (PGEN) reported long-term marketable securities of $489K in Q1 2026.
How has Precigen's long-term marketable securities changed year-over-year?: Precigen's long-term marketable securities decreased by 34.8% year-over-year, from $750K to $489K.